Asthma or Chronic Rhinosinusitis with Nasal Polyps Patient Survey
GAAPP Publications
Research News
From the Chief Scientific Officer Desk
Opportunities
COPD Patients and Caregivers: We need your voice and experience.
Do you have COPD? Do you have a family member with COPD? GAAPP has several opportunities every year for you to share your voice and experiences. If you are interested in more information, email us at info@gaapp.org.
If you are living with asthma and/or chronic rhinosinusitis with nasal polyps and reside in the US, Canada, UK, Germany, Italy, France, or Spain, your insights are invaluable.
GAAPP is leading this research survey with support from GSK. The results will contribute to developing better educational materials for patients and providers It is available online in 5 languages.
Outreach program decreases health care resource use among children with asthma.
A community outreach program decreased healthcare resource use among children with high-risk asthma in Tennessee by targeting specific barriers to care, according to a report published in Annals of Allergy, Asthma & Immunology. Patients who participated in the program experienced these improvements within a year of enrollment.
Read the publication written by Christie F. Michael, MD, associate professor in the department of pediatrics at The University of Tennessee Health Science Center, and colleagues HERE.
GAAPP has co-authored multiple-recent peer-reviewed publications. Please visit our website to check those publications and also access the latest guidelines from GINA, GOLD, EADV, AAI, and EAACI.
Patients who participated in research made it possible!
The first-ever treatment for adults and children with food allergies approved in the US.
A significant breakthrough for the Food Allergies community. The U.S. FDA has approved Xolair ®
(omalizumab), marking it the first-ever treatment for individuals with food allergies, including children and adults. The NIH-sponsored Phase III OUtMATCH study highlights its effectiveness against allergies to peanuts, tree nuts, eggs, milk, and wheat.
Learn more about Xolair.
DUPIXENT® (Dupilumab), which is approved in the US for several other indications, including asthma and eczema, has been accepted for FDA priority review, signaling a potential breakthrough for patients with #Type2Inflammation COPD. This decision was based on promising results from two Phase 3 trials in COPD. Dupixent could become the first biologic therapy for COPD and the first novel treatment method approved for COPD in over a decade.
GAAPP is proud to be a member of the global World Bronchiectasis Day collaboration, now on its third year. The theme for the 2024 event that will start on July 1st is centered around research, and we are excited to collaborate with the global organizing committee to advocate for our community on that special day.
We are looking forward to serving as a voice for our community at 2024 conferences, including the ATS in San Diego, CA, where GAAPP will present the results of our research.
A heartfelt welcome goes out to our new Research Intern, Madison Sprankle.
